Abstract
Background: Psoriasis (Pso) is a common chronic inflammatory disease affecting the skin, both sexes, and all ages. It can be associated with other chronic inflammatory musculoskeletal disorders and certain drugs, including tumor necrosis factor α (TNFα) antagonists.
Case Presentation: A 64-year-old man with seronegative rheumatoid arthritis (RA) refractory to leflunomide and prednisone was treated with SB-4 (Benepali), an etanercept biosimilar 50mg/week subcutaneously. He responded well to the treatment, but a year later, he developed erythematous skin eruptions affecting mainly in the palms of both hands. Skin biopsy showed a picture compatible with Pso. SB-4 was discontinued, and the skin lesions disappeared with the addition of topical steroid therapy. This is the only case of psoriatic skin lesions associated with SB-4 treatment. Conclusion: Thus, we review and discuss the relevant literature of Pso cases related to SB-4 and other anti-TNFα biosimilars. Rheumatologists dealing with patients on anti-TNFα biosimilars should be aware of and recognize these complications.Keywords: RA, TNF inhibitors, autoimmune phenomena, psoriatic skin lesions, SB-4, TNFα.
Graphical Abstract
[http://dx.doi.org/10.1186/1741-7015-11-88] [PMID: 23557513]
[http://dx.doi.org/10.1111/j.1398-9995.2006.01058.x] [PMID: 16867042]
[http://dx.doi.org/10.1097/00002281-200307000-00003] [PMID: 12819464]
[http://dx.doi.org/10.1016/j.clim.2007.08.012] [PMID: 17916445]
[http://dx.doi.org/10.1016/j.amjmed.2005.01.029] [PMID: 15866254]
[PMID: 22153557]
[http://dx.doi.org/10.1093/rap/rkz007] [PMID: 31431995]
[http://dx.doi.org/10.1016/j.semarthrit.2010.07.004] [PMID: 20843542]
[http://dx.doi.org/10.1007/s00296-007-0330-9] [PMID: 17357804]
[http://dx.doi.org/10.1016/j.jbspin.2010.02.014] [PMID: 20452801]
[PMID: 24447441]
[http://dx.doi.org/10.3390/jcm8030387] [PMID: 30897745]
[http://dx.doi.org/10.1002/art.21233] [PMID: 16052599]
[http://dx.doi.org/10.1136/ard.2007.075663] [PMID: 17728330]
[http://dx.doi.org/10.1080/03009740902922612] [PMID: 19579151]
[http://dx.doi.org/10.1080/14712598.2019.1566456] [PMID: 30616405]
[http://dx.doi.org/10.1001/archderm.143.2.223] [PMID: 17310002]
[http://dx.doi.org/10.1007/s00296-011-1999-3] [PMID: 21800117]
[http://dx.doi.org/10.1002/art.27584] [PMID: 20872595]
[http://dx.doi.org/10.1038/clpt.1981.154] [PMID: 7249508]
[http://dx.doi.org/10.1016/j.jaci.2015.10.023] [PMID: 26768759]
[http://dx.doi.org/10.1093/rheumatology/kev088.111]
[http://dx.doi.org/10.1093/rheumatology/ken091] [PMID: 18346974]
[http://dx.doi.org/10.1111/apt.15370] [PMID: 31267570]
[http://dx.doi.org/10.1016/j.autrev.2013.06.005] [PMID: 23777821]
[http://dx.doi.org/10.1038/ajg.2015.205] [PMID: 26195181]
[http://dx.doi.org/10.1084/jem.20050500] [PMID: 15998792]
[http://dx.doi.org/10.1073/pnas.0408506102] [PMID: 15728381]
[http://dx.doi.org/10.1111/j.1365-2133.2009.09329.x] [PMID: 19681863]